Authors' reply to whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: Scientific rationale and current evidence

CNS Drugs

Volumn 28, Issue 12, 2014, Pages 1207-1213

  Ignatowski, Tracey A ^a   Spengler, Robert N ^b   Tobinick, Edward ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b NanoAxis LLC   (United States)

^c Institute of Neurological Recovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; ESCITALOPRAM; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR; IMMUNOGLOBULIN G; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ACQUIRED BRAIN INJURY; ANALGESIA; BRAIN DYSFUNCTION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; COGNITIVE DEFECT; CONNECTOME; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMAN; LETTER; LOCUS CERULEUS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; PATHOGENESIS; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SCIATICA; SINGLE DRUG DOSE; SYSTEMIC THERAPY; ANIMAL; COGNITION DISORDERS; COMPLICATION; STROKE;

ANIMALS; COGNITION DISORDERS; HUMANS; IMMUNOGLOBULIN G; NEUROPROTECTIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; STROKE;

EID: 84922073814     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0212-0     Document Type: Letter

References (125)

1. Ignatowski TA, Covey WC, Knight PR, Severin CM, Nickola TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 1999;841(1-2):70-7.
2. Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res. 2000;859(1):113-22.
3. Covey WC, Ignatowski TA, Renauld AE, Knight PR, Nader ND, Spengler RN. Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain. Reg Anesth Pain Med. 2002;27(4):357-66.
4. Reynolds JL, Ignatowski TA, Spengler RN. Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor. J Neurosci Res. 2005;79(6):779-87.
5. Ignatowski TA, Spengler RN. Cytokines in synaptic function. In: Berczi I, Szentivanyi A, editors. Cytokines and the brain. NeuroImmune biology. Vol 6. Amsterdam: Elsevier; 2008. p. 111-43.
6. Martuscello RT, Spengler RN, Bonoiu AC, Davidson BA, Helinski J, Ding H, et al. Increasing TNF levels solely in the rat hippocampus produces persistent pain-like symptoms. Pain. 2012;153(9):1871-82.
7. Ignatowski TA, Gerard BA, Bonoiu AC, Mahajan S, Knight PR, Davidson BA, et al., editors. Reduction of tumor necrosis factor (TNF) in the hippocampus alleviates neuropathic pain perception. Proceedings of the 4th International Congress on Neuropathic Pain; 2013. pp 29-35.
8. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med. 2006;8(2):25.
9. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 2008;8:27.
10. Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.
11. Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. 2003;133(11-12):170-7.
12. Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin. 2004;20(7):1075-85.
13. Tobinick E. Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res. 2007;4(5):550-2.
14. Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflamm. 2008;5:3.
15. Maudsley S, Chadwick W. Progressive and unconventional pharmacotherapeutic approaches to Alzheimer's disease therapy. Curr Alzheimer Res. 2012;9(1):1-4.
16. Tobinick E. Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease. Curr Alzheimer Res. 2012;9(1):99-109.
17. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014;28(8):679-97.
18. Mohammadi D. INMiND: getting to the bottom of neuroinflammation. Lancet Neurol. 2013;12(12):1135-6.
19. NEURON. Call for proposals for "European Research Projects on Neuroinflammation", NEURON. 2014. http://www.neuron-eranet.eu/en/522.php. Accessed 9 Oct 2014.
20. Ransohoff R. Call for papers: Neurology: Neuroimmunology and Neuroinflammation, a new neurology journal. Neurology. 2014;82:648-9.
21. Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT. Effects of centrally administered etanercept on behaviour, microglia and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology. 2014;. doi: 10.1038/npp.2014.199.
22. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA. 2011;108(9):3731-6.
23. Schaefer A, Burmann I, Regenthal R, Arelin K, Barth C, Pampel A, et al. Serotonergic modulation of intrinsic functional connectivity. Cur Biol. 2014. doi: 10.1016/j.cub.2014.08.024.
24. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985-1002.
25. Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145-55.
26. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, Depuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051-70.
27. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflamm. 2008;5:2.
28. Rech J, Hess A, Finzel S, Kreitz S, Sergeeva M, Englbrecht M, et al. Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis. Arthritis Rheum. 2013;65(2):325-33.
29. Ignatowski TA, Spengler RN. Tumor necrosis factor-alpha: presynaptic sensitivity is modified after antidepressant drug administration. Brain Res. 1994;665(2):293-9.
30. Ignatowski TA, Noble BK, Wright JR, Gorfien JL, Heffner RR, Spengler RN. Neuronal-associated tumor necrosis factor (TNF alpha): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. J Neuroimmunol. 1997;79(1):84-90.
31. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr. 2014;14(1 Suppl):3-7.
32. Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. Clin Drug Investig. 2014;34(5):361-6.
33. Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;. doi: 10.1016/j.cytogfr.2014.07.016.
34. Pribiag H, Stellwagen D. Neuroimmune regulation of homeostatic synaptic plasticity. Neuropharmacology. 2014;78:13-22.
35. Olmos G, Llado J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediat inflamm. 2014;2014:861231.
36. Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer's disease. Drug Discov Today. 2014;. doi: 10.1016/j.drudis.2014.06.029.
37. Santello M, Volterra A. TNF-alpha in synaptic function: switching gears. Trends Neurosci. 2012;35(10):638-47.
38. Whitlock DR. Comment on: "Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence". CNS Drugs. 2014. doi: 10.1007/s40263-014-0211-1.
39. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
40. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009;102(5):186-94.
41. Kaplan BJ, Giesbrecht G, Shannon S, McLeod K. Evaluating treatments in health care: the instability of a one-legged stool. BMC Med Res Methodol. 2011;11:65.
42. Williams JK. Understanding evidence-based medicine: a primer. Am J Obstet Gynecol. 2001;185(2):275-8.
43. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349-51.
44. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. 2011. http://www.cebm.net/index.aspx?o=5653. Accessed 9 Oct 2014.
45. Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis. 2010;69(12):2067-73.
46. US FDA. Guidance for clinical investigators, spon'sors, and IRBs. Investigational new drug applications (INDs) - determining whether human research studies can be conducted without an IND. 2013. http://www.fda.gov/downloads/Drugs/Guidances/UCM229175.pdf. Accessed 9 Oct 2014.
47. Dacks PA, Bennett DA, Fillit HM. Evidence needs to be translated, whether or not it is complete. JAMA Neurol. 2014;71(2):137-8.
48. Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med. 2010;103(11):433-41.
49. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx. 2004;1(3):341-7.
50. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-92.
51. Trudeau DL. The value of observational studies in neurotherapy. J Neurother. 2001;4(3):1-4.
52. Grossman J, Mackenzie FJ. The randomized controlled trial: gold standard, or merely standard? Perspect Biol Med. 2005;48(4):516-34.
53. Demonaco HJ, Ali A, Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy. 2006;26(3):323-32.
54. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119-25.
55. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344(8930):1125-7.
56. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-2.
57. Vandenbroucke JP. Case reports in an evidence-based world. J R Soc Med. 1999;92(4):159-63.
58. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134(4):330-4.
59. Kiene H, Hamre HJ, Kienle GS. In support of clinical case reports: a system of causality assessment. Glob Adv Health Med. 2013;2(2):64-75.
60. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459-61.
61. Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med. 2008;10(6):135.
62. Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. Clin Drug Invest 2014; 34(5):361-66.
63. Coelho SC, Bastos-Pereira AL, Fraga D, Chichorro JG, Zampronio AR. Etanercept reduces thermal and mechanical orofacial hyperalgesia following inflammation and neuropathic injury. Eur J Pain. 2014;18(7):957-67.
64. Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC 3rd, Griffith S, Kurihara C, et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology. 2009;110(5):1116-26.
65. Freeman BJ, Ludbrook GL, Hall S, Cousins M, Mitchell B, Jaros M, et al. Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation. Spine. 2013;38(23):1986-94.
66. Holmes C, Butchart J, Wolfe L, Davies L, Dodge S, Lewsey I, et al. The safety and tolerability of etanercept in Alzheimer's disease (STEADI-09): a phase II double blind randomised placebo controlled trial 2014. Copenhagen: Alzheimer's Association International Conference; 2014.
67. Iwatsuki K, Arai T, Ota H, Kato S, Natsume T, Kurimoto S, et al. Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain. PloS One. 2013;8(2):e57721.
68. Kato K, Kikuchi S, Shubayev VI, Myers RR. Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience. 2009;160(2):492-500.
69. Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine. 2012;37(6):439-44.
70. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine. 2001;26(8):863-9.
71. Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota G, et al. Intradiscal administration of tumor necrosis factor-alpha inhibitor, etanercept, clinically improves intractable discogenic low back pain. Glob Spine J. 2014. doi: 10.1055/s-0034-1376544.
72. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, et al. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg. 2011;112(2):454-9.
73. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001;6(2):67-72.
74. Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009;14(3-4):168-77.
75. Tobinick E. Author's reply to Page. "Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept". CNS Drugs. 2013;27(5):399-402.
76. Tobinick EL. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin Ther. 2003;25(4):1211-8.
77. Watanabe K, Yabuki S, Sekiguchi M, Kikuchi S, Konno S. Etanercept attenuates pain-related behavior following compression of the dorsal root ganglion in the rat. Eur Spine J. 2011;20(11):1877-84.
78. Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M, Christoferson L, et al. Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model. Spine. 2008;33(3):227-34.
79. Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther. 2003;25(8):2279-88.
80. Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. Med Gen Med. 2006;8(1):53.
81. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs. 2009;23(9):713-25.
82. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014.
83. Ye J, Jiang R, Cui M, Zhu B, Sun L, Wang Y, et al. Etanercept reduces neuroinflammation and lethality in mouse model of Japanese encephalitis. J Infect Dis. 2014;210(6):875-89.
84. Winkelstein BA, Allen KD, Setton LA. Chapter 19: intervertebral disc herniation: pathophysiology and emerging therapies. In: Shapiro IM, Risbud MV, editors. The intervertebral disc. Wien: Springer; 2014.
85. Wilcox KS, Vezzani A. Does brain inflammation mediate pathological outcomes in epilepsy? Adv Exp Med Biol. 2014;813:169-83.
86. Wang K, Liu B, Ma J. Research progress in traumatic brain penumbra. Chin Med J. 2014;127(10):1964-8.
87. Walters ET. Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense. Exp Neurol. 2014;258C:48-61.
88. Viviani B, Boraso M, Marchetti N, Marinovich M. Perspectives on neuroinflammation and excitotoxicity: a neurotoxic conspiracy? Neurotoxicology. 2014;43:10-20.
89. Topdag M, Iseri M, Topdag DO, Kokturk S, Ozturk M, Iseri P. The effect of etanercept and methylprednisolone on functional recovery of the facial nerve after crush injury. Otol Neurotol. 2014;35(7):1277-83.
90. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, et al. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimer's Dis. 2014;41(3):877-86.
91. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014;25(2):131-7.
92. Ohtori S, Inoue G, Miyagi M, Takahashi K. Pathomechanisms of discogenic low back pain in humans and animal models. Spine J. 2014;. doi: 10.1016/j.spinee.2013.07.490.
93. Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W. Insulin resistance, neuroinflammation, and Alzheimer's disease. Rev Neurosci. 2014;25(4):509-25.
94. Kathirvelu B, Carmichael ST. Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery. Metab Brain Dis. 2014;. doi: 10.1007/s11011-014-9559-7.
95. Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous drainage of the spine and spinal cord: a comprehensive review of its history, embryology, anatomy, physiology, and pathology. Clin Anat. 2014;. doi: 10.1002/ca.22354.
96. Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, et al. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 2014;228(1):78-85.
97. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimer's dement J Alzheimer's Assoc. 2014;10(1S):S76-83.
98. Faingold CL. Network control mechanisms: cellular inputs, neuroactive substances, and synaptic changes. In: Faingold CL, Blumenfeld H, editors. Neuronal networks in brain function. CNS Disorders, and Therapeutics: Elsevier; 2014.
99. Ekici MA, Uysal O, Cikriklar HI, Ozbek Z, Turgut Cosan D, Baydemir C, et al. Effect of etanercept and lithium chloride on preventing secondary tissue damage in rats with experimental diffuse severe brain injury. Eur Rev Med Pharmacol Sci. 2014;18(1):10-27.
100. Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochem Int. 2014;. doi: 10.1016/j.neuint.2014.04.001.
101. Yoshiyama Y, Lee VM, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry. 2013;84(7):784-95.
102. Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. J Cereb Blood Flow Metab. 2013;33(9):1376-85.
103. Waters RJ, Murray GD, Teasdale GM, Stewart J, Day I, Lee RJ, et al. Cytokine gene polymorphisms and outcome after traumatic brain injury. J Neurotrauma. 2013;30(20):1710-6.
104. Swardfager W, Winer DA, Herrmann N, Winer S, Lanctot KL. Interleukin-17 in post-stroke neurodegeneration. Neurosci Biobehav Rev. 2013;37(3):436-47.
105. Shi X, Zhou W, Huang H, Zhu H, Zhou P, Zhu H, et al. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Critical Care. 2013;17(6):R301.
106. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013;84(9):956-62.
107. Lei B, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT, James ML. Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflamm. 2013;10(1):103.
108. Kaufman EL, Carl A. Biochemistry of back pain. Open Spine J. 2013;5:12-8.
109. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(Pt 1):28-42.
110. Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, et al. Documentation of off-label use of biologics in rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii35-51.
111. Efrati S, Fishlev G, Bechor Y, Volkov O, Bergan J, Kliakhandler K, et al. Hyperbaric oxygen induces late neuroplasticity in post stroke patients: randomized, prospective trial. PloS One. 2013;8(1):e53716.
112. Clark IA, Vissel B. Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem Pharmacol. 2013;86(7):862-71.
113. Chio CC, Chang CH, Wang CC, Cheong CU, Chao CM, Cheng BC, et al. Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha. BMC Neurosci. 2013;14(1):33.
114. Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-alpha contents and by stimulating newly formed neurogenesis. Mediat Inflamm. 2013;2013:620837.
115. Butterworth RF. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nature Rev Gastroenterol Hepatol. 2013;10(9):522-8.
116. Brambilla L, Martorana F, Rossi D. Astrocyte signaling and neurodegeneration: new insights into CNS disorders. Prion. 2013;7(1):28-36.
117. Boivin N, Menasria R, Piret J, Rivest S, Boivin G. The combination of valacyclovir with an anti-TNF alpha antibody (etanercept) increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. Antivir Res. 2013;100(3):649-53.
118. Blaylock RL. Immunology primer for neurosurgeons and neurologists part 2: innate brain immunity. Surg Neurol Int. 2013;4:118.
119. Bai L, Song N, Yu J, Tan L, Shen Y, Xie J, et al. Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of northern Han Chinese descent. Curr Alzheimer Res. 2013;10(1):57-62.
120. Williams M, Coyle JT. Historical perspectives on the discovery and development of drugs to treat neurological disorders. In: Barrett JE, Coyle JT, Williams M, editors. Translational neuroscience: applications in psychiatry, neurology, and neurodevelopmental disorders. New York: Cambridge University Press; 2012. p. 129-48.
121. Clark I. New hope for survivors of stroke and traumatic brain injury. CNS Drugs. 2012;26(12):1071-2.
122. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev. 2012;64(4):1004-26.
123. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344(21):1594-602.
124. Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;(1):CD003974.
125. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, et al. Stroke: working toward a prioritized world agenda. Stroke. 2010;41(6):1084-99.